Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P42785
UPID:
PCP_HUMAN
Alternative names:
Angiotensinase C; Lysosomal carboxypeptidase C; Proline carboxypeptidase; Prolylcarboxypeptidase
Alternative UPACC:
P42785; A8MU24; B2R7B7; B3KRK5; B5BU34
Background:
Lysosomal Pro-X carboxypeptidase, also known as Angiotensinase C, Lysosomal carboxypeptidase C, Proline carboxypeptidase, and Prolylcarboxypeptidase, plays a crucial role in the cleavage of C-terminal amino acids linked to proline in peptides such as angiotensin II, III, and des-Arg9-bradykinin. This enzymatic activity, predominantly occurring at acidic pH, retains its function with some substrates even at neutral pH.
Therapeutic significance:
Understanding the role of Lysosomal Pro-X carboxypeptidase could open doors to potential therapeutic strategies.